| Status | Study |
| Recruiting |
Study Name: Lymphatic Anomalies Registry Condition: Lymphatic Malformation Generalized Lymphatic Anomaly (GLA) Date: 2015-03-17 |
| Recruiting |
Study Name: Sildenafil for the Treatment of Lymphatic Malformations Condition: Lymphatic Malformations Lymphatic Diseases Date: 2015-01-07 Interventions: Drug: Sildenafil 20 mg tablets Other: Plac |
| Completed |
Study Name: A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations Condition: Lymphangioma Date: 2011-02-03 Interventions: Drug: Sildenafil Sildenafil oral tablet three times daily |
| Terminated |
Study Name: Selenium in the Treatment of Complicated Lymphatic Malformations Condition: Lymphatic Malformations Date: 2010-09-24 Interventions: Drug: Selenium 400 μg once a day for 6 months by mouth |
| Active, not recruiting |
Study Name: Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies Condition: Kaposiform Hemangioendotheliomas Tufted Angioma Capillary Date: 2009-09-10 Interventions: Drug: sirolimus liquid dosing based on trough levels |
| Completed |
Study Name: Diagnosis of Hemangiomas and Vascular Malformations Condition: Hemangiomas Vascular Malformations Venular Malformations Date: 2007-12-18 |
| Recruiting |
Study Name: Registry for Vascular Anomalies Associated With Coagulopathy Condition: Multifocal Lymphangioendotheliomatosis With Thrombocytopenia Cutaneovisceral Angiomatosis Wi Date: 2007-12-18 Interventions: Other: no intervention no intervention - observational only |
| Active, not recruiting |
Study Name: Airway Vascular Lesions Condition: Hemangiomas Venous Malformations Lym Date: 2007-12-17 Interventions: Other: Protocols for Treatment Determine protocols for treatment of airway vascular malformation and to |
| Completed |
Study Name: Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options. Condition: Vascular Anomalies Date: 2005-12-02 Interventions: Drug: Marimastat |
| Completed |
Study Name: Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations Condition: Lymphatic Malformations Date: 2001-02-02 Interventions: Drug: picibanil Up to .2 mg per injection, given intralesionally every 6-8 weeks |